Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
Follow AGEN
Agenus Inc. (AGEN) Piotroski F-score
Agenus Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 2.00 |
| FY2024 | 2 | (1.00) |
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | (5.00) |
| FY2021 | 7 | 5.00 |
| FY2020 | 2 | (2.00) |
| FY2019 | 4 | 2.00 |
| FY2018 | 2 | 0.00 |
| FY2017 | 2 | 0.00 |
| FY2016 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (0.04%) | (84.20%) | Fail | 0 |
| Positive operating cash flow | (77.19m) | (158.31m) | Fail | 0 |
| Rising return on assets | (0.04%) | (84.20%) | Pass | 1 |
| Cash flow above net income | (77.09m) | 69.11m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.11 | Pass | 1 |
| Rising current ratio | 0.41 | 0.21 | Pass | 1 |
| No new shares issued | 29,734,000 | 21,473,000 | Fail | 0 |
| Rising gross margin | 99.11% | 99.53% | Fail | 0 |
| Rising asset turnover | 0.50 | 0.38 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | 5 |
| AGEN Agenus Inc. | 4 |
| BNTC Benitec Biopharma Limited compare | 3 |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 2 |
| OCGN Ocugen, Inc. compare | 2 |
| SRZN Surrozen, Inc. compare | — |
| CTNM Contineum Therapeutics, Inc. compare | — |
| CYPH Cypherpunk Technologies Inc. compare | — |
| ARTV Artiva Biotherapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover